| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1 Edinburgh and South East Scotland Blood Transfusion Service, Royal Infirmary of Edinburgh, Lauriston Place, Edinburgh EH3 9HB, UK
2 Murex Diagnostics Ltd, Central Road, Temple Hill, Dartford DA1 5LR, Kent, UK
3 Department of Medical Microbiology, University of Edinburgh, Teviot Place, Edinburgh EH8 9AG, UK
4 Unit of Hepatology, Aker University of Hospital, 0514 Oslo 5, Norway
5 Cairo Liver Centre, 5 El-Girgawy Street, Dokki, Cairo, Egypt
6 University of Witwatersrand, Johannesburg 2193, South Africa
The7 Natal Institute of Immunology, Robin Road, 3610, South Africa
8 Hong Kong Red Cross, Kowloon, Hong Kong
9 Institute of Virology, Church Street, Glasgow G11 5JR, UK
and10 Riyadh Armed Forces Hospital, Riyadh 11159, Saudi Arabia
The 5' end of the NS-4 protein of different genotypes of hepatitis C virus (HCV) is highly variable in nucleotide and inferred amino acid sequence, with frequent predicted amino acid substitutions between all six of the major HCV genotypes described to date. This region has been shown to be antigenic by epitope mapping, and elicits antibody in HCV-infected individuals with a detectable type-specific component. We have used this sequence data to specify branched peptides for an indirect binding/competition assay to detect type-specific antibody to each major genotype. A total of 183 out of 210 samples (87%) from blood donors and patients with chronic hepatitis C infected with genotypes 1 to 6 showed detectable type-specific antibody to NS-4 peptides that in almost all cases (> 97%) corresponded to the genotype detected by a PCR typing method. These findings demonstrate the existence of major antigenic differences between genotypes of HCV, and indicate how infection with different variants of HCV may be detected by a serological test.
* Author for correspondence. Fax +44 131 650 6531.
Received 19 December 1994;
accepted 27 February 1995.
This article has been cited by other articles:
|
|
 |
|
  S M Kamal, A A El Tawil, T Nakano, Q He, J Rasenack, S A Hakam, W A Saleh, A Ismail, A A Aziz, and M A. Madwar Peginterferon {alpha}-2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response Gut, June 1, 2005; 54(6): 858 - 866. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Gault, P. Soussan, Y. Morice, L. Sanders, A. Berrada, B. Rogers, and P. Deny Evaluation of a New Serotyping Assay for Detection of Anti-Hepatitis C Virus Type-Specific Antibodies in Serum Samples J. Clin. Microbiol., May 1, 2003; 41(5): 2084 - 2087. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Halfon, P. Trimoulet, M. Bourliere, H. Khiri, V. de Lédinghen, P. Couzigou, J. M. Feryn, P. Alcaraz, C. Renou, H. J. A. Fleury, et al. Hepatitis C Virus Genotyping Based on 5' Noncoding Sequence Analysis (Trugene) J. Clin. Microbiol., May 1, 2001; 39(5): 1771 - 1773. [Abstract] [Full Text]
|
|
|
|
 |
|
 K. Abid, R. Quadri, A.-L. Veuthey, A. Hadengue, and F. Negro A novel hepatitis C virus (HCV) subtype from Somalia and its classification into HCV clade 3 J. Gen. Virol., June 1, 2000; 81(6): 1485 - 1493. [Abstract] [Full Text]
|
|
|
|
|
|
M. Schröter, H.-H. Feucht, P. Schäfer, B. Zöllner, and R. Laufs Serological Determination of Hepatitis C Virus Subtypes 1a, 1b, 2a, 2b, 3a, and 4a by a Recombinant Immunoblot Assay J. Clin. Microbiol., August 1, 1999; 37(8): 2576 - 2580. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. Songsivilai, D. Kanistanon, and T. Dharakul A Serotyping Assay for Hepatitis C Virus in Southeast Asia Clin. Vaccine Immunol., September 1, 1998; 5(5): 737 - 739. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| INT J SYST EVOL MICROBIOL | MICROBIOLOGY | J GEN VIROL |
| J MED MICROBIOL | ALL SGM JOURNALS | |
